HANSOH PHARMA(HK:03692) Zhi Tong Cai Jing·2025-08-19 02:04Core Viewpoint - Hansoh Pharmaceutical (03692) experienced a nearly 6% increase in stock price following the release of its interim results, reflecting positive market sentiment towards the company's financial performance and growth prospects [1] Financial Performance - The company reported a revenue of 7.434 billion RMB, representing a year-on-year increase of 14.27% [1] - The profit attributable to the parent company was 3.135 billion RMB, up 15.02% year-on-year [1] - Earnings per share were reported at 0.53 RMB, with a proposed interim dividend of 0.2316 HKD per share [1] Product Sales - The sales revenue from innovative drugs in China amounted to approximately 6.145 billion RMB, accounting for about 82.7% of total revenue [1] - The company has seven innovative drugs generating sales revenue [1] Strategic Developments - In June, the company announced the grant of exclusive overseas rights for the GLP-1/GIP dual receptor agonist HS-20094, with a potential total amount exceeding 2 billion USD [1] - Clinical studies for HS-20094 have involved over 1,000 participants, and the drug is currently advancing to Phase III clinical trials for obesity or overweight indications [1] - The company received an upfront payment of 80 million USD in July related to this agreement [1]